拓扑替康
医学
内科学
肺癌
危险系数
肿瘤科
临床终点
人口
化疗
临床试验
置信区间
环境卫生
作者
Nobuyuki Takahashi,Zhonglin Hao,Liza C. Villaruz,Jun Zhang,Jimmy Ruiz,W. Jeffrey Petty,Hirva Mamdani,Jonathan W. Riess,Jorge J. Nieva,Jose M. Pachecho,Alexander D. Fuld,Elaine Shum,Aman Chauhan,Samantha Nichols,Hirity Shimellis,Jessie McGlone,Linda Sciuto,Danielle Pinkiert,Chante Graham,Meenakshi Shelat
出处
期刊：JAMA Oncology
[American Medical Association]
日期：2023-10-12
卷期号：9 (12): 1669-1669
被引量：19
标识
DOI：10.1001/jamaoncol.2023.4025
摘要
Patients with relapsed small cell lung cancer (SCLC), a high replication stress tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor activity with the addition of the ataxia telangiectasia and Rad3-related kinase inhibitor berzosertib to topotecan.
科研通智能强力驱动
Strongly Powered by AbleSci AI
nozero
zho
昏睡的蟠桃
从容芮
cdercder
小杨同学
bc
今天只做一件事
爱静静
小透明
科研小民工
压缩机
贰鸟
英勇的鼠标
PKUBruce
CAOHOU
shinysparrow
竹筏过海
back you up
yy
皖公网安备34019202002308
